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a b s t r a c t
Atherosclerosis is an inﬂammatory disorder of the vasculature that is orchestrated by the action of
cytokines. Macrophages play a prominent role in all stages of this disease, including foam cell forma-
tion, production of reactive oxygen species, modulation of the inﬂammatory response and the regulation
of the stability of atherosclerotic plaques. The role of the matrix metalloproteinase family in the con-
trol of plaque stability is well established. A disintegrin and metalloproteinase with thrombospondin
motif (ADAMTS) family has been implicated in several diseases and the expression of ADAMTS-4 in
macrophages of atherosclerotic lesions has suggested a potential role for this protease in atherosclerosis.
However, the action of cytokines on the expression of ADAMTS-4 in macrophages is poorly understood.
We have investigated here the effect of transforming growth factor- (TGF-) on ADAMTS-4 expression
in macrophages along with the regulatory mechanisms underlying its actions. Consistent with the anti-
atherogenic role of TGF-, this cytokine decreased the expression of ADAMTS-4 mRNA and protein in
human macrophages. Transient transfection assays showed that the −100 to +10 promoter region con-
tained the minimal TGF- response elements. Small-interfering RNA-mediated knockdown revealed a
critical role for Smads, p38mitogen-activatedprotein kinase and c-Jun in the actionof TGF-onADAMTS-
4mRNAexpression. These studies show for the ﬁrst time that TGF- inhibits the expression of ADAMTS-4
in human macrophages and identiﬁes the signalling pathways underlying this response. The inhibition
of macrophage ADAMTS-4 expression is likely to contribute to the anti-atherogenic, plaque stabilisation
action of TGF-.
. Introduction
A disintegrin and metalloproteinase with thrombospondin
otifs (ADAMTS) proteases are non-membrane bound enzymes
hat are able to interactwith and degrade components of the extra-
ellular matrix (ECM), such as pro-collagen and hyalectans (Salter
t al., 2010; Jones and Riley, 2005; Porter et al., 2005). Of the
DAMTS proteases identiﬁed to date, ADAMTS-1 and ADAMTS-4
re the most abundant and consequently have been the subject
f the majority of research on these enzymes (Salter et al., 2010;
ones and Riley, 2005). There has been much focus on the ability
f ADAMTS proteases to cleave aggrecan, a proteoglycan present
n articular cartilage (Salter et al., 2010; Naito et al., 2007; Tang,
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2001). Cleavage of aggrecan in human cartilage contributes to the
pathophysiology of osteoarthritis and rheumatoid arthritis and a
role for ADAMTS-4 in this process has been deﬁned (Salter et al.,
2010; Naito et al., 2007; Tang, 2001).
A possible role for the ADAMTS proteases as contributors to
inﬂammation and atherosclerosis has only recently come to light
(Salter et al., 2010). Atherosclerosis, the primary cause of coro-
nary heart disease, is an inﬂammatory disorder orchestrated by
the action of cytokines. The latter stages of this disease are asso-
ciated with the migration and the proliferation of vascular smooth
muscle cells (VSMCs),which leads to theproductionof the extracel-
lularmatrix and the formationof aﬁbrous cap in the atherosclerotic
Open access under CC BY-NC-ND license.plaque (Bui et al., 2009). The balance between the synthesis and the
degradation of the ECM by matrix metalloproteinases (MMPs) and
other proteases determines the susceptibility of the plaque to rup-
ture and subsequent thrombosis and myocardial infarction (Li and
Glass, 2002; Lusis et al., 2004).
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The ADAMTS proteases were ﬁrst associated with inﬂammation
hen it was shown that administration of lipopolysaccharide (LPS)
n vivo could enhance ADAMTS-1 expression in the heart and in the
idneys (Kuno et al., 1997). ADAMTS-1, -4 and -8 have been found
o be present within atherosclerotic lesions and mice overexpress-
ng ADAMTS-1 crossed with ApoE-deﬁcient mice, an animal model
or atherosclerosis, showed increased thickening of the arterial
ntima (Wight, 2005; Jonsson-Rylander et al., 2005;Wågsäter et al.,
008). ADAMTS-4 is predominantly associated with macrophages
f atherosclerotic lesions and its expression is increased following
oth monocyte–macrophage differentiation and during develop-
ent of atherosclerosis in a mouse model system (Wågsäter et al.,
008). The ability of the ADAMTS proteases to cleave proteoglycans
s likely to be central to any proposed role in atherosclerosis. Both
DAMTS-1and -4are able to cleaveversican, a proteoglycan similar
n structure to aggrecan but predominantly expressed in the vas-
ulature (Sandy et al., 2001). Versican expression is upregulated in
ascular disease, accumulates in atherosclerotic plaques (Worley
t al., 2003) and can be cleaved by ADAMTS-1 and ADAMTS-4 at
peciﬁc Glu-Ala bonds (Sandy et al., 2001). It has also been shown
hat in the human aorta, versican fragments can be generated
y ADAMTS-1 and ADAMTS-4 digestion of intact human versican
Sandy et al., 2001).
Very few studies have investigated the regulation of ADAMTS
rotease expression in macrophages and further studies are nec-
ssary especially as ADAMTS-4 has been found to colocalize with
acrophages of atherosclerotic lesions (Wågsäter et al., 2008). To
ur knowledge only one study has been carried out that investi-
ated the expression of ADAMTSproteases in response to cytokines
n human macrophages and this demonstrated that ADAMTS-4
xpression was up-regulated by the pro-inﬂammatory cytokines
nterferon- (IFN-) and tumour necrosis factor- (Wågsäter et al.,
008).
TGF- is a major anti-atherogenic cytokine and inhibition of its
ctions, using neutralising antibodies or expression of a dominant
egative receptor, has been found to accelerate the development
f atherosclerosis in mouse models of this disease (Singh and
amji, 2006a). The cytokine inhibits foam cell formation and an
nverse relationship has been identiﬁed between circulating levels
f TGF- and the development of atherosclerosis (Singh and Ramji,
006a). In addition, regions in the aorta with low TGF- expres-
ion have a high probability of developing atherosclerosis (Singh
nd Ramji, 2006a). TGF- is also known to inhibit the expression of
MPs, which decrease plaque stability via thinning of the ﬁbrous
laque through cleavage of collagens, elastins and other proteogly-
ans in the ECM (Galis and Khatri, 2002; Singh and Ramji, 2006a;
ewby, 2007). In light of such a potent anti-atherogenic role of
GF-, we examined its action on ADAMTS-4 expression in human
acrophages with a view to further investigating the molecular
echanisms underlying such regulation.We showhere that TGF-
own-regulates ADAMTS-4 expression at the level of mRNA, pro-
ein and promoter activity. In addition, our studies demonstrate
critical role for Smads, p38 mitogen-activated protein kinase
MAPK) and c-Jun in the regulation of ADAMTS-4 by TGF-.
. Materials and methods
.1. Reagents
The humanmonocytic leukaemia THP-1 cell line and the human
epatoma Hep3B cell line were obtained from the European
ollection of Animal Cell Cultures (ECACC). Human recombi-
ant TGF-1 was from Peprotech, validated Smad-2, c-Jun and
xtracellular signal-regulated kinase (ERK) 1/2 small interfering
NA (siRNA) was from Qiagen and validated Smad-3 and p38hemistry & Cell Biology 43 (2011) 805–811
MAPK siRNA was from Invitrogen. Antibodies were from Afﬁn-
ity Bioreagents (ADAMTS-4), Cell Signaling Technology (Smad2/3,
p38MAPK, ERK1/2), Santa Cruz Biotechnology (c-Jun) and Sigma
(-actin). SuperfectTM transfection reagent was from Qiagen and
INTERFERinTM from Polyplus Transfection.
2.2. Cell culture
Thecell linesweremaintained ineitherDMEM(Hep3B)orRPMI-
1640 (THP-1) supplemented with 10% (v/v) heat-inactivated fetal
calf serum, 100U/ml penicillin and 100g/ml Streptomycin. The
culturesweremaintained in a humidiﬁed atmosphere at 37 ◦C con-
taining 5% (v/v) CO2. THP-1 monocytes were differentiated into
macrophages using 0.16g/ml phorbol 12-myristate 13-acetate
(PMA). For human monocyte-derived macrophages (HMDMs),
Ficoll–Hypaque puriﬁcationwas used to isolate the cells frombuffy
coats (McLaren et al., 2010a,b; Li et al., 2010). Blood layered over
LymphoprepTM (Nycomed Pharmaceuticals) in AccuspinTM tubes
(Sigma) was centrifuged and platelets removed from the mononu-
clear cell interface by washing several times with PBS, containing
0.4% (v/v) tri-sodium citrate. Monocytes were plated out in RPMI-
1640 supplemented as described above, except containing 5% (v/v)
fetal calf serum, and left to differentiate into macrophages for 7
days.
2.3. Transfection of siRNA
THP-1 monocytes were transfected with 7.5nM siRNA using
INTERFERinTM essentially as described by the manufacturer (Poly-
Plus Transfection). The cells were then incubated for 24h before
differentiation intomacrophagesusingPMAasdescribedaboveand
subsequent treatment with TGF- (30ng/ml). Gene silencing was
measured 48h after transfection by Western blot analysis.
2.4. Real-time quantitative PCR (RT-qPCR)
RT-qPCR was carried out using primers against ADAMTS-4
or the ribosomal protein L13A (RPL13A) or the glyceraldehyde
3-dehydrogenase (GAPDH) control genes and the SYBR® Green
JumpStartTM Taq ReadyMixTM (Sigma) on a DNA Engine Opticon
2® real-time PCR detection system (MJ Research). The sequences
of the primers were 5′-GGGATAGTGACCACATTGTT-3′ and 5′-
AGGCACTGGGCTACTACTAT-3′ for ADAMTS-4; 5′-CCTGGAGGAGA-
AGAGGAAAGAGA-3′ and 5′-TTGAGGACCTCTGTGTATTTGTCAA-3′
for RPL13A; and 5′-GAAGGTGAAGGTCGGAGTC-3′ and 5′-
GAAGATGGTGATGGGATTTC-3′ for GAPDH. For each transcript
a standard curve was constructed using a recombinant pGEM-T
plasmid containing the PCR product generated for each speciﬁc
set of primers. A melting curve was constructed to verify single
product ampliﬁcation and the comparative Ct method was used
for analysis and normalisation to the control transcript levels.
2.5. Transient transfection assays
Hep3B and U937 cells were transfected using SuperfectTM.
Transfection of U937 cells was carried out as previously described
(Hughes et al., 2002; Irvine et al., 2005). For Hep3B, the cells were
subcultured at a ratio of 1:6 into 12-well plates 24h prior to trans-
fection andmediumreplacedwith freshDMEMbefore transfection.
The DNA:SuperfectTM mix was prepared according to the man-
ufacturer’s instructions (Qiagen) in 50l medium containing no
antibiotics or serum. The mixture was incubated at room tem-
perature for 10min and then diluted with DMEM medium before
being added to the cells. The cells were then left for 30min and
then treated with vehicle or TGF- (30ng/ml) for 24h. The cells
were then harvested using 1× passive lysis buffer (Promega) and
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Fig. 1. TGF- inhibits ADAMTS-4 mRNA expression in THP-1 macrophages. THP-1
macrophages were treated for 24h with the indicated concentration of TGF- (A) or
with 30ng/ml of this cytokine for the time points shown (B). Total RNA was isolated
and subjected to RT-qPCR. The Ct method was used for analysis and the values for
ADAMTS-4 were normalised to the control gene GAPDH (A) or RPL13A (B). The dataR.C. Salter et al. / The International Journal o
he luciferase activity measured using a commercially available kit
Promega). The luciferase activity was normalised to total protein
evels as determined using the micro BCA protein assay kit accord-
ng to the manufacturer’s instructions (Pierce).
.6. Western blot analysis
Samples were prepared in Laemmli buffer and size-fractionated
nder reducing conditions using 10% SDS-polyacrylamide gels
nd transferred to a PVDF membrane (Millipore) by Western
lotting (Ali et al., 2010). Incubation with primary and sec-
ndary antibodies and chemiluminescent detection was carried
ut as described previously (Ali et al., 2010). Samples were sub-
ected to electrophoresis alongside comparative molecular weight
arkers (GE Healthcare) to determine the size of the protein
roduct. Membranes were developed using chemiluminescence
etection reagents (GE Healthcare) and Kodak XAR sensitive ﬁlm
Sigma).
.7. Statistical analysis of data
Statistical comparisons of data were carried out using Stu-
ent’s t test with P<0.05 considered statistically signiﬁcant.
emi-quantitative, densitometric analysis of Western blot signals
as performed using the GeneTools software (GRI).
. Results
.1. TGF-ˇ inhibits ADAMTS-4 expression at the mRNA and
rotein level in THP-1 macrophages and HMDMs
The action of TGF- on the expression of ADAMTS-4 in human
acrophages has not been determined and was therefore investi-
ated. The THP-1 monocytic cell line, which can be differentiated
nto macrophages using PMA, is used extensively to investi-
ate macrophage gene expression in relation to atherosclerosis
ecause of demonstrated conservation of responses with primary
acrophage cultures, in particular gene regulation by cytokines
Auwerx, 1991; McLaren et al., 2010a,b; Li et al., 2010).
Our previous studies on the TGF--mediated activation of
polipoproteinEexpression showedmaximal response at 24hwith
0ng/ml of the cytokine (Singh and Ramji, 2006b). We therefore
arried out dose–response RT-qPCR experiments on ADAMTS-4
sing the24h incubationperiod.As shown inFig. 1A, amarked inhi-
ition of ADAMTS-4 mRNA expression was observed with 2ng/ml
GF- with maximal suppression using 30ng/ml of this cytokine.
urther time course experiments using 30ng/ml of the cytokine
howed that ADAMTS-4 mRNA expression was down-regulated by
GF-within 1hof treatment and this responsewas sustained over
he 24h time period. Subsequent experiments were carried out
sing 30ng/ml of TGF- for an incubation period of 24h, unless
therwise stated.
To determine whether this down-regulation was accompanied
y a corresponding change in the level of protein, the expression
f ADAMTS-4 was investigated using Western blot analysis. Pre-
iminary experiments showed that the expression of ADAMTS-4
rotein was decreased with delayed kinetics compared to RNA
data not shown) so longer incubation periods were used for West-
rn blot analysis. Fig. 2A shows that ADAMTS-4 protein expression
as signiﬁcantly down-regulated in THP-1 macrophages by TGF-
treatment. In the light of these results and to conﬁrm that the
GF--mediated decrease in ADAMTS-4 expression was not pecu-
iar to the THP-1 cell line, we decided to carry out representative
xperiments in primary cultures of HMDMs. For this, the action of
GF- on ADAMTS-4 protein expression was determined. Fig. 2Bshows the expression relative to the 0ng/ml (A) or 0h (B) (arbitrarily assigned as
1) (mean± SD from three independent experiments). Asterisks indicate signiﬁcant
down-regulation of ADAMTS-4 mRNA expression (*P<0.05, **P<0.01, ***P<0.001).
shows that protein expression of ADAMTS-4 was down-regulated
by TGF- in these primary cultures.
3.2. TGF-ˇ inhibits ADAMTS-4 promoter activity
In order to investigate whether the action of TGF- was medi-
ated, at least in part, at the transcriptional level through the
regulation of promoter activity, the effect of this cytokine on
ADAMTS-4 promoter activity in transfected cells was determined.
Becauseofdifﬁculties in transfecting theTHP-1cell linewithexoge-
nous DNA, most experiments were carried out using the human
hepatomaHep3B cell line. These cells are used extensively to inves-
tigate the regulation of gene expression by cytokines in relation to
inﬂammation (acute-phase response) with demonstrated conser-
vation of responses to primary cultures (Foka et al., 2003, 2009
and references therein). Western blot analysis showed that TGF-
also inhibits ADAMTS-4 expression in these cells (Fig. 3), thereby
showing that the response was also conserved in hepatocytes. The
48h time point was chosen for experiments in these cells as it
corresponded to maximal decrease in ADAMTS-4 expression as
identiﬁed by preliminary time course analysis (data not shown).
We employed four promoter deletion constructs linked to the
luciferase gene: −726/+406 (p1132-LUC); −383/+406 (p789-LUC);
−100/+406 (p506-LUC); and +11/+406 (p396-LUC) (Fig. 4A) (Mizui
et al., 2000). A TGF--mediated decrease in promoter activity was
obtainedwith the p1132-LUC, p789-LUC andp-506-LUC constructs
but not with the p-396-LUC construct (Fig. 4B). This suggests that
808 R.C. Salter et al. / The International Journal of Biochemistry & Cell Biology 43 (2011) 805–811
Fig. 2. TGF- inhibits ADAMTS-4 protein expression in macrophages. THP-1
macrophages (A) or HMDMs (B) were either left untreated (UT) or incubated with
30ng/ml TGF- for the timepoints indicated. An equal amount of the protein extract
was subjected to Western blot analysis using antisera against ADAMTS-4 and the
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Fig. 3. TGF- inhibits ADAMTS-4 protein expression in Hep3B cells. The cells were
either left untreated (UT) or incubated with TGF- for 48h. Equal amounts of pro-
tein were subjected to Western blot analysis using antisera against ADAMTS-4 andontrol-actin, as shown. The relative ADAMTS-4 expression normalised to-actin,
s determined by densitometric analysis, from three independent experiments is
hown (mean± SD) with the values from untreated cells arbitrarily assigned as 1
*P<0.05; **P<0.01; ***P<0.001).
he minimal TGF- response elements reside between the −100
nd the +10 region. Similar resultswere obtainedwhen representa-
ive experimentswere carried out using humanU937macrophages
Fig. 4C) [the luciferase reporter gene activity from the +11/+406
p396-LUC) construct in these cells was negligible and was there-
ore not included for further analysis].
.3. The action of TGF-ˇ on ADAMTS-4 expression requires
mads, p38 MAPK and c-JunTGF-mediates many of its actions through the classical Smad
ignalling pathway with the three MAPK pathways [ERK, c-Jun N-
erminal kinase (JNK) and p38 MAPK] required in the regulation of
ertain genes (Ten Dijke and Hill, 2004). Most of these studies havethe control -actin, as indicated. The relative ADAMTS-4 expression normalised to
-actin, as determined by densitometric analysis, from three independent experi-
ments is shown (mean± SD)with the value fromuntreated cells arbitrarily assigned
as 1 (*P<0.05).
been carried out in relation to the TGF--mediated induction of
geneexpressionandvery little is currentlyunderstood in relation to
the inhibition of gene expression. We therefore analysed whether
the Smad or MAPK pathways had any role in the regulation of
ADAMTS-4 expression by this cytokine. Thiswas investigated using
siRNA-mediated RNA interference assays and RT-qPCR analysis. As
in a number of previous studies, GAPDH siRNA was used as a con-
trol (Ali et al., 2010) and this had no effect on the TGF--mediated
inhibition of ADAMTS-4 expression (Fig. 5). Knockdown of Smad-2
plus 3, ERK 1/2, c-Jun, a key downstream target of the JNK path-
way, and p38 MAPK was achieved using commercially validated
siRNA sequences and relative expression of each protein following
siRNA-mediatedknockdownwas conﬁrmed inTHP-1macrophages
by Western blot analysis (Fig. 5A). The TGF--mediated inhibition
of ADAMTS-4 expression was attenuated by knockdown of Smad-
2 plus -3 (Fig. 5B). In addition, the TGF--mediated inhibition of
ADAMTS-4 expression was attenuated by knockdown of c-Jun and
p38 MAPK but not ERK1/2 (Fig. 5B). Because the expression of
ADAMTS-4 is induced during monocyte–macrophage differentia-
tion (Wågsäter et al., 2008), the effect of these knockdown on the
constitutive expression of ADAMTS-4 in macrophages, driven by
thedifferentiationprocess,was alsodetermined. Thiswas inhibited
by knockdown of only p38 MAPK but not Smad-2 plus -3, ERK1/2
or c-Jun (Fig. 6).
4. Discussion
Several members of the ADAMTS family have been linked
with inﬂammation but their role in this and in pathophysiologi-
cal inﬂammatory states including atherosclerosis is only beginning
to be researched (Salter et al., 2010). Although the exact role of the
ADAMTS proteases in atherosclerosis remains unclear it is thought
that the ability of ADAMTS-1 and -4 to cleave versican, the pri-
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Fig. 4. TGF- inhibits ADAMTS-4 promoter activity. (A) Schematic representation of
the different ADAMTS-4 promoter-luciferase DNA constructs used. Hep3B cells (B)
and U937 monocytes (C) were transfected with the ADAMTS-4 promoter-luciferase
DNA constructs using SuperfectTM. The cells were either left untreated or treated
overnight with 30ng/ml TGF- (1M PMA was also included for U937 only to ini-
tiate differentiation) and cell lysates were measured for luciferase activity. Data
shown is the ratio of luciferase activity:protein concentration expressed as the fold
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Fig. 5. The effect of siRNA-mediated knockdown of key components of the TGF-
signalling pathway on the inhibition of ADAMTS-4 expression by this cytokine. THP-
1monocyteswere transfectedwith validated siRNA against Smad-2 and -3, ERK 1/2,
c-Jun or p38 MAPK as shown. Cells were incubated with siRNA for 24h before dif-
ferentiation for 24h with PMA and subsequently being either left untreated (UT)
or stimulated with 30ng/ml TGF- for 24h. Total RNA and protein was then puri-
ﬁed. (A) siRNA-mediated knockdown was veriﬁed by Western blot analysis using
antisera against total Smad-2 and -3, ERK 1/2, c-Jun, p38 MAPK (p38) and -actin,
as indicated. The image shown is representative of three independent experiments.
The histogram shows relative expression (mean± SD) of each protein normalised
to -actin, as determined by densitometric analysis, with the values from GAPDH
siRNA-transfected cells being arbitrarily assigned as 1 (*P<0.05, **P<0.01). (B) Total
transfection of ADAMTS-4 promoter deletion constructs demon-hange in activity relative to the equivalent untreated sample (arbitrarily assigned
s 1) and is representative of three independent experiments (NS, not signiﬁcant,
P<0.05, **P<0.01, ***P<0.001).
ary proteoglycan component of the vasculature, is likely to be
entral to any hypothesised role in the disease (Salter et al., 2010;
orley et al., 2003). The production and secretion of proteases
y smooth muscle cells and by macrophages is a key regulatory
ction during atherosclerosis (Bui et al., 2009). The vulnerability of
he atherosclerotic plaque is determined by the balance between
he synthesis and the degradation of the ECM. This degradation is
chieved through the action of MMPs and other proteases such as
he ADAMTS proteases, which cleave the collagens and proteogly-
ans of the ECM (Galis and Khatri, 2002; Newby, 2007).
We demonstrate for the ﬁrst time that ADAMTS-4 mRNA and
rotein expression is inhibited by the anti-atherogenic cytokine
GF- in THP-1 macrophages and HMDMs (Figs. 1 and 2). The
esponse is also conserved in hepatocytes (Fig. 3). This novel
nding is consistent with the work of Wågsäter et al. (2008) who
ound that ADAMTS-4 mRNA expression can be up-regulated
y the pro-inﬂammatory cytokines IFN- and TNF- in THP-1
acrophages. In addition to this, TGF- has been demonstrated
o inhibit the expression of a number of MMPs, including MMP-1
White et al., 2000), MMP-3 (Kerr et al., 1990) and MMP-9 (Ogawa
t al., 2004). In our studies, down-regulation of ADAMTS-4 mRNARNA was subjected to RT-qPCR and the ADAMTS-4 expression was normalised to
the control gene RPL13A and presented as the fold change relative to the untreated
sample for each siRNA, which was arbitrarily assigned as 1. The data shown is
representative of three independent experiments (NS, not signiﬁcant, **P<0.01).
expression by TGF-was observed within 1h and continued up to
24h of treatment with this cytokine (Fig. 1).
In addition to characterising the response of ADAMTS-4 to TGF-
,wealso identify the regulatory regionof theADAMTS-4promoter
involved in this response. We show here that ADAMTS-4 promoter
activity was suppressed by TGF- treatment (Fig. 4). Transientstrates an involvement of the −100/+10 region in the negative
regulation of the ADAMTS-4 promoter by TGF- (Fig. 4). Of the
ADAMTSproteases, only thepromotersofADAMTS-4andADAMTS-
5 have been characterised (Mizui et al., 2000; Thirunavukkarasu
810 R.C. Salter et al. / The International Journal of Biochemistry & Cell Biology 43 (2011) 805–811
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elative constitutive mRNA expression of ADAMTS-4 (i.e. in the absence of TGF-)
APDH-transfected sample (assigned as 1) from three independent experiments, is
t al., 2006, 2007). Mizui et al. (2000) have identiﬁed the −383 to
10 sequence of the ADAMTS-4 promoter as the region required for
ull promoter activity. In addition, analysis of the promoter activity
f various deletion constructs suggested that the region between
726 and−384was likely to contain silencer elements (Mizui et al.,
000).
We also show that the Smad pathway is required in the action of
GF- on ADAMTS-4 expression. The Smads are the classical trans-
ucers of the TGF- signal (Ross and Hill, 2008) and Smad-2, -3
nd -4 are expressed in macrophages and foam cells of atheroscle-
otic lesions (Kalinina et al., 2004). Following siRNA-mediated
nockdown of Smad-2 plus -3, the TGF--mediated inhibition of
DAMTS-4 mRNA expression was no longer signiﬁcant (Fig. 5).
mads have been implicated in the repression of a number of
enes by TGF- including monocyte chemoattractant protein-1,
nvolved in the recruitment ofmonocytes in inﬂammatory vascular
isease states (Feinberg et al., 2004), and the scavenger receptor
D36, which has been shown to be regulated by a reduction in
eroxisome proliferator-activated receptor- activity mediated by
GF- through Smad-3 and the activator protein-1 (AP-1) family
Fu et al., 2003). In addition, our data suggest an involvement of
APKs as the TGF--mediated inhibition of ADAMTS-4 was no
onger signiﬁcant following siRNA-mediated knockdown of p38
APKand c-Jun (a keydownstream target for JNKpathway) (Fig. 5).
n contrast, the ERK pathway was not involved (Fig. 5). TGF- is
ble to activate the MAPK pathways (Ten Dijke and Hill, 2004)
ut whether this acts independently or in conjunction with the
lassical Smad pathway is unclear. Smads have been shown to
nteract with the c-Jun and c-fos proteins, components of the AP-
transcription factor complex (Verrecchia and Mauviel, 2002),
nd the TGF--mediated inhibition of MMP-1 expression has been
hown to be dependent on the interaction between Smads and
he AP-1 site present within the MMP-1 promoter (Hall et al.,
003).
Several cytokines are present in atherosclerotic lesions and
he action of combinations of cytokines on gene expression and
ellular changes is likely to be more profound than that pro-
uced by a single cytokine. For example, our previous studies have
hown that there is a synergism between IFN- and TNF- in
he regulation of macrophage lipoprotein lipase gene expression
Tengku-Muhammad et al., 1998). On the other hand, IFN- antag-
nises the action of TGF- (Ulloa et al., 1999). Future studies should
herefore investigate the action of combinations of cytokines on
DAMTS-4 expression.TS-4 in THP-1 macrophages. The experiments were carried out as Fig. 5 and the
alised to the control gene RPL13A and presented as a fold change relative to the
n (NS, not signiﬁcant, *P<0.05).
In conclusion, we have shown that ADAMTS-4 is negatively
regulated by TGF- in human macrophages and that this regu-
lation requires Smads, p38 MAPK and c-Jun. We have identiﬁed
the minimal regulatory promoter region involved in this response.
These ﬁndings are likely to be important for atherosclerosis given
the potent anti-atherogenic action of TGF-, as demonstrated by
numerous studies in vitro and in vivo, and the demonstrated crucial
role of proteases in the regulation of plaque stability. It is therefore
essential that the role of ADAMTS-4 in the regulation of atheroscle-
rosis in mouse model systems is determined.
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